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Is yearly chest x-ray screening helpful 
in reducing mortality for smokers?
■ Evidence summary
Five randomized controlled trials have
examined lung cancer mortality after
screening chest x-rays. In the first trial—the
only one that included former as well as
current smokers and nonsmokers—
subjects were randomized to undergo chest
x-ray studies every 6 months, or at baseline
and again at the end of the 3-year study.
After 3 years, there was no statistically 
significant mortality difference with more
frequent chest x-rays.1,2
Another trial involved male smokers
who were randomized to undergo chest x-
ray and sputum cytology either every 6
months or after 3 years. After 3 years, both
groups were screened annually with chest
x-ray alone for an additional 3 years.
There was no significant difference in lung
cancer mortality at any point, including at
a 15-year post-trial follow-up.3 Both stud-
ies showed earlier detection and longer
survivorship of lung cancer among
screened vs nonscreened groups due to
lead-time bias (because the cancer was
detected earlier from screening vs clinical
diagnosis, it falsely appears to prolong sur-
vival). Overall mortality was the same in
both groups. 
The National Cancer Institute (NCI)
sponsored 3 randomized controlled trials
on lung cancer screening for male smokers
involving 3 major medical centers. The
studies were designed to determine the
incremental benefit of adding sputum
cytology to chest x-ray screening. In 2 of
the NCI studies, participants were 
randomly assigned to receive annual chest
x-ray only or a dual screen with annual
chest x-ray and sputum cytologies every 4
months. In both studies, there was no sta-
tistical difference in lung cancer mortality
between the 2 groups.4–6 The third NCI
study randomized participants to chest 
Reduce morbidity and mortality 
by helping patients quit smoking
The bottom line is that morbidity and mortality 
are not reduced when we use chest x-rays, 
sputum cytology, or a combination of the 2 in
screening for lung cancer. One thing we can do 
for our patients is counsel them about the ill
effects of tobacco use and support them in their
smoking cessation efforts. Although there is no
guarantee that those who quit will not get lung
cancer, cessation certainly reduces the risk and
brings other health and financial benefits. 
Of interest is the ongoing National Lung
Screening trial, which compares screening 
spiral CT scans with chest x-rays in the detection
of lung cancer. This large trial, sponsored by the
NCI, will compare both modalities over 8 years
and should help determine if either test is better
at reducing morbidity and mortality from this 
disease. 
For current and former smokers, the evidence 
does not support yearly chest x-rays to decrease
lung cancer mortality (strength of recommendation
[SOR]: A, based on multiple randomized 
controlled trials). Even with the addition of 
sputum cytology and more frequent chest 
x-rays, lung cancer mortality was unchanged
(SOR: A).
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x-ray and sputum cytology either every 
4 months or annually. Again, there was no
significant difference in lung cancer mor-
tality,4 even after an extended follow-up of
20.5 years.7 Adding sputum cytology to
chest x-ray only improved lung cancer
detection rates over chest x-ray alone.
A significant limitation of the 5 studies
presented is that no true control or non-
screening groups determined the real effi-
cacy of screening chest x-rays vs no screen-
ing. The goal of a study of a screening 
program is to detect a disease early enough
so that treatment can alter mortality. These
uncontrolled studies of routine screening
chest x-rays, no matter how frequently
performed, do not meet this criteria for
current and former smokers.
Recommendations from others
The US Preventive Services Task Force
does not recommend for or against screen-
ing asymptomatic or high-risk persons for
lung cancer with either low-dose comput-
ed tomography (CT), chest x-ray, sputum
cytology, or a combination of these tests.8
The American Cancer Society and
American Academy of Family Physicians
recommend against the use of chest x-ray
or sputum cytology in asymptomatic high-
risk persons.9,10 The American College of
Chest Physicians recommends against the
use of serial chest x-rays for individuals
without symptoms or without a history of
cancer.11 They do not comment about
high-risk groups—that is, current or 
former smokers.
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